Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been found to have a positive effect on liver steatosis, inflammation, and fibrosis, making them a potential treatment for MASH. Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.